BIOBOHEMIA
This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
Close
Our company
and technology
© Biobohemia 2019 | SANTAVACTM
Our company
and technology
© Biobohemia 2019 | SANTAVACTM
Biobohemia is a biotechnology company engaged in research and development of innovative proprietary products in the field of oncology, and have discovered a potentially non-toxic, selective and targeted approach for treating various forms of cancer.

Biobohemia's lead product, SANTAVACTM (Set of All Natural Target Antigens for Vaccination Against Cancer) is an antigen composition developed by proteomics and cell culture technology and intended for development of cancer vaccines against solid tumors. The mechanism of action of SANTAVACTM is based on the heterogeneity of endothelial cells, consisting of polypeptides similar to surface antigens of tumor-vessels cells allowing targeted destruction by vaccination. The SANTAVACTM efficacy and mechanism of action is presented in series of peer-reviewed scientific papers.
SANTAVACTM has no analogues in the world in terms of the selectivity of its anti-tumor immunity.
Among the methods of immunotherapy of malignant neoplasms, vaccination against the vessels supplying the tumor (antiangiogenic vaccines) is the most promising and attractive because it can hinder the growth of absolutely any tumors. Unfortunately, effective anti-angiogenic anticancer vaccines have not yet been created. This is due to the fact that the first attempts were simply vaccination with vascular cells that did not justify themselves. Our innovative antigenic formulation (SANTAVACTM) is a breakthrough in the development of anti-angiogenic vaccines, which was created using modern proteomic and bioinformatics technologies. We have found that tumors induce specific changes in the vessels that feed them, the use of which provides the basis for creating effective vaccines that destroy these vessels. Our scientific papers demonstrate this data and describe the found most effective composition of SANTAVACTM.

SANTAVACTM is designed to create on its basis a variety of tumor vaccines, by mixing it with an adjuvant and experimental testing (in vitro studies, cytotoxic tests, model experiments, etc.). Created as a pharmaceutical product, SANTAVACTM is currently ready for use and can only be purchased for R&D purposes. For preclinical and clinical trials of vaccines based on SANTAVACTM, vaccines must be prepared in accordance with regulatory requirements.

Potential users of SANTAVACTM: commercial and non-profit organizations involved in the development of any type of anticancer vaccines (therapeutic or prophylactic anticancer vaccines, adjuvant or dendritic cell vaccines).
Among the methods of immunotherapy of malignant neoplasms, vaccination against the vessels supplying the tumor (antiangiogenic vaccines) is the most promising and attractive because it can hinder the growth of absolutely any tumors. Unfortunately, effective anti-angiogenic anticancer vaccines have not yet been created. This is due to the fact that the first attempts were simply vaccination with vascular cells that did not justify themselves. Our innovative antigenic formulation (SANTAVACTM) is a breakthrough in the development of anti-angiogenic vaccines, which was created using modern proteomic and bioinformatics technologies. We have found that tumors induce specific changes in the vessels that feed them, the use of which provides the basis for creating effective vaccines that destroy these vessels. Our scientific papers demonstrate this data and describe the found most effective composition of SANTAVACTM.

SANTAVACTM is designed to create on its basis a variety of tumor vaccines, by mixing it with an adjuvant and experimental testing (in vitro studies, cytotoxic tests, model experiments, etc.). Created as a pharmaceutical product, SANTAVACTM is currently ready for use and can only be purchased for R&D purposes. For preclinical and clinical trials of vaccines based on SANTAVACTM, vaccines must be prepared in accordance with regulatory requirements.

Potential users of SANTAVACTM: commercial and non-profit organizations involved in the development of any type of anticancer vaccines (therapeutic or prophylactic anticancer vaccines, adjuvant or dendritic cell vaccines).